19T.F IDORSIA AG
- Market cap
- EUR 1.20B
- P/E
- -
- P/B
- 6.32x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 19T.F undervalued?
Graham numberThe Graham number of IDORSIA AG cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
IDORSIA AG fundamental analysis
No fundamental analysis for IDORSIA AG yet.
IDORSIA AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About IDORSIA AG
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company's product pipeline includes Lucerastat, a gl…
Full company profileIDORSIA AG financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
IDORSIA AG annual financial statements (CHF; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 35.3M | 97.1M | 152M | 113M | 221M | 230M |
| Gross Profit | 35.3M | 90.8M | 145M | 76.6M | 200M | 186M |
| Operating Income | -613M | -803M | -543M | -337M | -116M | -132M |
| EBITDA | - | -783M | -255M | -226M | -45.5M | -116M |
| Net Income | -635M | -828M | -298M | -264M | -112M | -274M |
| EPS | -3.59 | -4.66 | -1.67 | -1.40 | -0.45 | -1.02 |
| Balance Sheet | ||||||
| Total Assets | 1.48B | 904M | 500M | 506M | 466M | 462M |
| Total Liabilities | 1.38B | 1.57B | 1.47B | 1.72B | 1.60B | 1.69B |
| Shareholders' Equity | 104M | -661M | -969M | -1.21B | -1.14B | -1.23B |
| Cash & Short-term Investments | 101M | 146M | 145M | 105M | 87.2M | 85.1M |
| Cash Flow | ||||||
| Operating Cash Flow | -590M | -859M | -629M | -370M | -153M | -92.3M |
| Capital Expenditure | 30.9M | 27.1M | 9.40M | 18.0M | 13.8M | 8.75M |
| Free Cash Flow | -621M | -886M | -639M | -388M | -167M | -101M |
| Ratios | ||||||
| ROE | -609.0% | - | - | - | - | - |
| ROA | -42.8% | -91.6% | -59.6% | -52.1% | -24.0% | -59.4% |
| Net Profit Margin | -1,795.2% | -852.6% | -195.5% | -234.4% | -50.6% | -119.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
IDORSIA AG dividends
IDORSIA AG has not paid dividends in the last 5 fiscal years.
Who owns IDORSIA AG
- Insiders 30.19%
- Institutions 36.64%
- Public & others 33.17%
- Shares outstanding 270M
- Free float 156M
IDORSIA AG company profile
- Company name
- IDORSIA AG
- Ticker
- 19T.F
- ISIN
- CH0363463438
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 424
- Fiscal year end
- December
- Address
- Hegenheimermattweg 91, Allschwil, Switzerland, 4123
- Phone
- 41 58 844 10 10
- Website
- idorsia.com
About IDORSIA AG
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company's product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial to treat fabry disease; Daridorexant, a dual orexin receptor antagonist, which is in phase 2 clinical trial for the treatment of pediatric insomnia; IDOR-1117-2520, a CCR6 receptor antagonist which is in phase 1 clinical program to treat psoriasis; ACT-777991, a CXCR3 antagonist, which is in preclinical trial to treat vitiligo; and ACT-1004-1239, an ACKR3 receptor antagonist which is preclinical trial for the treatment of progressive multiple sclerosis. It also develops ACT-1016-0707, a LPA 1 receptor antagonist to treat immune-mediated and fibrosis related disorders; IDOR-1141-8472, an orexin 2 receptor agonist to treat orexin-related CNS disorders; and IDOR-1126-6421 to treat organ injury. The company holds a license agreement with Neuro to develop and commercialize clazosentan; collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; and collaboration with Viatris Inc. to develop and commercialize selatogrel and cenerimod. Idorsia Ltd was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
IDORSIA AG management
10- Arno GroenewoudExecutive VP & CFO · born 1971
- Dr. Martine ClozelExecutive VP, Chief Scientific Officer & Head of Research · born 1955
- Mr. Julien Gander L.L.M.Executive VP, Chief Legal & Corporate Development Officer and Company Secretary · born 1979
- Dr. Roland Wandeler Ph.D.Chief Executive Officer · born 1972
- Amel DjedourSenior VP & Head of Technical Operations · born 1976
- Andrew JonesSenior VP, Head of Corporate Communications & Investor Relations · born 1975
- Gaby SchererSenior VP & Head of Global Human Resources · born 1961
- Mr. Benjamin LimalExecutive VP and President of Europe & International Markets Region · born 1973
- Dr. Amer JosephExecutive VP, Chief Medical Officer & Head of Global Clinical Development · born 1983
- Mr. Shalom JacobovitzPresident of Idorsia US · born 1961